Melinda Burgess

Melinda Burgess serves as an Industry Fellow at the Frazer Institute, University of Queensland, focusing on translational cancer research with particular emphasis on chronic lymphocytic leukemia (CLL) and immunotherapy resistance mechanisms. Her work bridges laboratory discoveries with clinical applications, investigating how tumor microenvironments and immune cells influence treatment outcomes.

Her primary research domains include:

• Chronic Lymphocytic Leukemia pathogenesis and treatment resistance
• Macrophage and nurse-like cell biology in hematological malignancies
• Therapeutic antibody mechanisms and resistance pathways
• siRNA delivery systems for cancer gene therapy
• Novel targets for overcoming immunotherapy resistance

Analysis of her 17 journal publications (2010-2023) reveals a cohesive research trajectory centered on CLL resistance mechanisms. Key findings include identification of FcγRIIB dominance, HDAC7 overexpression, and PI3K-p110δ signaling as critical drivers of therapeutic antibody resistance in macrophages. Her recent work extends to combination therapies involving PD-1 blockade and investigation of concomitant malignancies. Publications span high-impact journals including Oncogene, Leukemia, and Frontiers in Immunology.

Dr. Burgess maintains extensive collaborations with University of Queensland researchers including Nicholas Saunders, Peter Mollee, and Devinder Gill. No information regarding educational background, scientific awards, or student advising activities was provided in the source materials.